Back to Authors

Fryer, James P.

A5103615846 | I1330342723

Mayo Clinic

Mayo Clinic

Citations 45

Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder

Neurology | June 18, 2020 | Volume: 95 | Issue: 2 | Pages: No page available

10.1212/wnl.0000000000009758 | PMID 32554760

Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD

Neurology Neuroimmunology & Neuroinflammation | May 28, 2020 | Volume: 7 | Issue: 4 | Pages: No page available

10.1212/nxi.0000000000000727 | PMID 35413004

Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica

Neurology | October 2, 2019 | Volume: 93 | Issue: 18 | Pages: No page available

10.1212/wnl.0000000000008394 | PMID 31578302

Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody

JAMA Neurology | December 21, 2018 | Volume: 76 | Issue: 3 | Pages: 301

10.1001/jamaneurol.2018.4053 | PMID 30575890

Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG–Associated Disorders

JAMA Neurology | July 16, 2018 | Volume: 75 | Issue: 11 | Pages: 1355

10.1001/jamaneurol.2018.1814 | PMID 30014148

Autoimmune septin-5 cerebellar ataxia

Neurology Neuroimmunology & Neuroinflammation | July 9, 2018 | Volume: 5 | Issue: 5 | Pages: No page available

10.1212/nxi.0000000000000474 | PMID 29998156

Novel Glial Targets and Recurrent Longitudinally Extensive Transverse Myelitis

JAMA Neurology | April 28, 2018 | Volume: 75 | Issue: 7 | Pages: 892

10.1001/jamaneurol.2018.0805 | PMID 29710213

Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4–IgG in Patients in the Optic Neuritis Treatment Trial

JAMA Ophthalmology | February 22, 2018 | Volume: 136 | Issue: 4 | Pages: 419

10.1001/jamaophthalmol.2017.6757 | PMID 29470571

Clinical utility of testing AQP4-IgG in CSF

Neurology Neuroimmunology & Neuroinflammation | April 21, 2016 | Volume: 3 | Issue: 3 | Pages: No page available

10.1212/nxi.0000000000000231 | PMID 27144221

Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrum

Annals of Neurology | February 18, 2016 | Volume: 79 | Issue: 5 | Pages: 775-783

10.1002/ana.24617 | PMID 26891082

ObjectiveNeuromyelitis optica (NMO) and its spectrum disorders (NMOSD) are inflammatory demyelinating diseases (IDDs) with a specific biomarker, aquaporin‐4–immunoglobulin G (AQP4‐IgG). Prior NMO/NMOSD epidemiological studies have been limited by lack of AQP4‐IgG seroprevalence assessment, absence of population‐based USA studies, and under‐representation of blacks. To overcome these limitations, we sought to compare NMO/NMOSD seroepidemiology across 2 ethnically divergent populations.MethodsWe performed a population‐based comparative study of the incidence (2003–2011) and prevalence (on December 31, 2011) of NMO/NMOSD and AQP4‐IgG seroincidence and seroprevalence (sera collected in 80–84% of IDD cases) among patients with IDD diagnosis in Olmsted County, Minnesota (82% white [Caucasian]) and Martinique (90% black [Afro‐Caribbean]). AQP4‐IgG was measured by M1 isoform fluorescence‐activated cell‐sorting assays.ResultsThe age‐ and sex‐adjusted incidence (7.3 vs 0.7/1,000,000 person‐years [p < 0.01]) and prevalence (10 vs 3.9/100,000 [p = 0.01]) in Martinique exceeded that in Olmsted County. The AQP4‐IgG age‐ and sex‐adjusted seroincidence (6.5 vs 0.7/1,000,000 person‐years [p < 0.01]) and seroprevalence (7.9 vs 3.3/100,000 [p = 0.04]) were also higher in Martinique than Olmsted County. The ethnicity‐specific prevalence was similar in Martinique and Olmsted County: 11.5 and 13/100,000 in blacks, and 6.1 and 4.0/100,000 in whites, respectively. NMO/NMOSD represented a higher proportion of IDD cases in Martinique than Olmsted County (16% vs 1.4%; p < 0.01). The onset age (median = 35–37 years) and female:male distribution (5–9:1) were similar across both populations; 60% of prevalent cases were either blind in 1 eye, dependent on a gait aid, or both.InterpretationThis study reports the highest prevalence of NMO/NMOSD in any population (10/100,000 in Martinique), estimates it affects 16,000 to 17,000 in the USA (higher than previous predictions), and demonstrates it disproportionately affects blacks. Ann Neurol 2016;79:775–783